Press Release

June 25, 2026 The Department of Corporate Services- Listing The Department of Corporate Services- Listing BSE Ltd, National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street Bandra Kurla Complex, Mumbai-400 001 Bandra (E) Mumbai – 400 051 Scrip Code: 507789 Symbol: JAGSNPHARM Subject: Press Release on appointment of Independent director of the Company Dear Sir/ Madam, Please find enclosed herewith a copy of the Press Release relating to Appointment of Mr. Anil Kumar Matai (DIN: 03122685) as an Additional Director in the category of Non-Executive Independent Director. We request you to take the above on record. Thanking you, Yours faithfully, For Jagsonpal Pharmaceuticals Limited Pratham Rawal Company Secretary & Compliance Officer Industry Veteran Anil Kumar Matai joins the Board of Jagsonpal Pharmaceuticals as an Independent Director Gurugram, India | June 25, 2026 – Jagsonpal Pharmaceuticals Ltd. today announced the appointment of Mr. Anil Kumar Matai as an Independent Director on the Board of the Company, effective June 25, 2026, subject to approval of the shareholders. Mr. Matai brings with him more than three decades of distinguished leadership experience across the pharmaceutical and healthcare sectors. Throughout his illustrious career, he has held senior leadership positions and has played a pivotal role in driving strategic growth, business transformation and operational excellence. Commenting on the appointment, Manish Gupta, Managing Director, stated: "We are delighted to welcome Mr. Anil Kumar Matai to the Jagsonpal family. With his rich experience and deep understanding of the pharmaceutical and healthcare industry, Mr. Matai brings valuable will be instrumental as we continue to scale our business and pursue new growth opportunities. Mr. Anil Kumar Matai said: "I am delighted to join the Board of Jagsonpal Pharmaceuticals and look forward to collaborating with the Board and management team. I hope to leverage my experience and understanding of the pharmaceutical industry to contribute to the Company’s growth, strengthen performance and create value for all stakeholders." ABOUT JAGSONPAL PHARMACEUTICALS LIMITED Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company with a proven track record of over four decades in the Indian pharmaceutical market. The Company has a robust portfolio of drugs focusing on Gynaecology, Orthopaedics, Dermatology and Child-care segments. Over the years, the Company has successfully built multiple brands that today hold market-leading positions in their respective segments. It has created a strong niche for itself with 20+ brands amongst Top 5 brands in the molecule category, extensive pan-India presence and an experienced sales team of over 1000 professionals. The company is listed on the National Stock Exchange Limited (JAGSNPHARM) and Bombay Stock Exchange (Scrip code: 507789) and is headquartered in Delhi. For more information, please visit: www.jagsonpal.com Company contact Investor Relations Team Email: cs@jagsonpal.com, Soumya Chhajed Tel: +91 124 4406710 Email- soumya@goindiaadvisors.com Mobile: +91-8619707750 Jagsonpal Pharmaceuticals Limited CIN: L74899DL1978PLC009181 Registered Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 Corporate Office: Nimai Tower, 3rd floor, Udyog Vihar, Gurugram, Haryana – 122015